These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 3558857

  • 21. Clinically-occult mixed cellularity Hodgkin's disease with Charcot-Leyden crystals.
    Carson HJ, Pellettiere EV.
    Leuk Lymphoma; 1996 Sep; 23(1-2):153-7. PubMed ID: 9021699
    [Abstract] [Full Text] [Related]

  • 22. Hodgkin's disease associated with raised eosinophil counts.
    Tauro GP.
    Med J Aust; 1966 Sep 24; 2(13):604-6. PubMed ID: 5921552
    [No Abstract] [Full Text] [Related]

  • 23. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H.
    J Clin Oncol; 1999 Mar 24; 17(3):776-83. PubMed ID: 10071266
    [Abstract] [Full Text] [Related]

  • 24. Histopathology of Hodgkin's lymphoma.
    Eberle FC, Mani H, Jaffe ES.
    Cancer J; 2009 Mar 24; 15(2):129-37. PubMed ID: 19390308
    [Abstract] [Full Text] [Related]

  • 25. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.
    Lancet Oncol; 2017 Apr 24; 18(4):454-463. PubMed ID: 28236583
    [Abstract] [Full Text] [Related]

  • 26. [Eosinophilic fasciitis and Hodgkin's disease].
    Rodat O, Harousseau JL, Reynaud C, Milpied N, Stalder JF, Chupin M.
    Sem Hop; 1982 Oct 21; 58(38):2207-9. PubMed ID: 6294863
    [Abstract] [Full Text] [Related]

  • 27. Systemic lupus erythematosus and Hodgkin's lymphoma.
    Bhalla R, Ajmani HS, Kim WW, Swedler WI, Lazarevic MB, Skosey JL.
    J Rheumatol; 1993 Aug 21; 20(8):1316-20. PubMed ID: 8230011
    [Abstract] [Full Text] [Related]

  • 28. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA.
    BMJ; 1992 May 02; 304(6835):1137-43. PubMed ID: 1392790
    [Abstract] [Full Text] [Related]

  • 29. Eosinophilia in Hodgkin's disease: a role for interleukin 5.
    Di Biagio E, Sánchez-Borges M, Desenne JJ, Suárez-Chacón R, Somoza R, Acquatella G.
    Int Arch Allergy Immunol; 1996 Jul 02; 110(3):244-51. PubMed ID: 8688671
    [Abstract] [Full Text] [Related]

  • 30. The pretreatment peripheral blood lymphocyte count in 1100 patients with Hodgkin's disease: the prognostic significance and the relationship to the presence of systemic symptoms.
    MacLennan KA, Hudson BV, Jelliffe AM, Haybittle JL, Hudson GV.
    Clin Oncol; 1981 Dec 02; 7(4):333-9. PubMed ID: 7318276
    [No Abstract] [Full Text] [Related]

  • 31. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
    Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Karkantaris C, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Pizzolo G, Pangalis GA.
    Haematologica; 2002 Jul 02; 87(7):701-8; discussion 708. PubMed ID: 12091120
    [Abstract] [Full Text] [Related]

  • 32. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
    Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, Uyttebroeck A, Bechter O, Delforge M, Vandecaveye V, Brison N, Verhoef GE, Legius E, Amant F, Vermeesch JR.
    Lancet Haematol; 2015 Feb 02; 2(2):e55-65. PubMed ID: 26687610
    [Abstract] [Full Text] [Related]

  • 33. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct 02; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 34. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
    Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, Halbsguth TV, Hitz F, Soekler M, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P, German Hodgkin Study Group.
    Lancet Oncol; 2016 Oct 02; 17(10):1453-1462. PubMed ID: 27612583
    [Abstract] [Full Text] [Related]

  • 35. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, Silver B, Weinstein H, Come S, Canellos GP, Coleman CN.
    Cancer J Sci Am; 1995 Oct 02; 1(1):33-42. PubMed ID: 9166452
    [Abstract] [Full Text] [Related]

  • 36. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J.
    Biol Blood Marrow Transplant; 1997 Jun 02; 3(2):98-106. PubMed ID: 9267670
    [Abstract] [Full Text] [Related]

  • 37. Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death.
    Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P, de Fine Olivarius N, Bjerrum OW.
    Am J Hematol; 2013 Oct 02; 88(10):843-7. PubMed ID: 23765950
    [Abstract] [Full Text] [Related]

  • 38. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
    Marcus KC, Kalish LA, Coleman CN, Shulman LN, Rosenthal DS, Canellos GP, Mauch PM.
    J Clin Oncol; 1994 Dec 02; 12(12):2567-72. PubMed ID: 7989930
    [Abstract] [Full Text] [Related]

  • 39. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ, Daugherty CK, Larson RA.
    Bone Marrow Transplant; 1997 Sep 02; 20(5):369-74. PubMed ID: 9339751
    [Abstract] [Full Text] [Related]

  • 40. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
    Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R, Costanza M, Bono E, Molo S, Maffi A, Croci GA, Varettoni M, Frigeni M, Pascutto C, Arcaini L, Bonfichi M, Paulli M, Cazzola M.
    Hematol Oncol; 2017 Sep 02; 35(3):296-302. PubMed ID: 27060262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.